Pseudovirus News and Research

RSS

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

A new study reports the results of a study focused on immune evasion characteristics, specifically the ability to escape neutralization by antibodies to the earlier SARS-CoV-2 variants or to the spike antigen used in COVID-19 vaccines.

16 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Scientists from Germany have recently pointed out that the third booster dose of mRNA-based COVID-19 vaccine is highly effective in neutralizing the omicron variant of SARS-CoV-2.

15 Dec 2021

Researchers develop a universal SARS-CoV-2 neutralizing antibody

A new study has been published in Frontiers in Immunology, where scientists developed a universal SARS-CoV-2 neutralizing antibody, MG1141A.

13 Dec 2021

A method to eliminate mutants in the furin cleavage site of SARS-CoV-2 in Calu-3 cells

...

12 Dec 2021

Neutralization antibodies elevated in nursing home residents after COVID-19 mRNA boosters

Researchers from the United States, in their recent study published on the preprint server medRxiv*, have evaluated the humoral responses to third vaccine dose in nursing home residents and healthcare workers (HCW) and found that that second booster (or third vaccine dose) significantly increased anti-spike, anti-receptor binding domain (RBD), and neutralization titers in almost all nursing home residents and HCW to considerably higher levels than what was attained after the completion of the initial two-dose vaccine series.

8 Dec 2021

Study suggests algal polysaccharide may be a promising anti-COVID-19 candidate

Researchers from the Rensselaer Polytechnic Institute have been investigating the potential of rhamnan sulfate as an antiviral agent.

7 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Sino Biological Launches A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)

Sino Biological, Inc. (https://www.sinobiological.com; SHE: 301047) announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus

From Sino Biological Inc. 6 Dec 2021

Preclinical data shows enhanced T-cell responses & neutralization of SARS-CoV-2 variants with ImmunityBio heterologous vaccination

A new study supports the hypothesis that heterologous vaccination can provide an increased immune response against virus infection, supporting several other studies that have indicated similar events.

5 Dec 2021

The emergence and evolution of SARS-CoV-2 and its VOCs

A review article discusses the evolution of SARS-CoV-2 and the emergence of variants of concern.

5 Dec 2021

Researchers report antibody cocktails are promising candidate tools for controlling new SARS-CoV-2 variants

Researchers from Academia Sinica in Taiwan have been investigating new antibodies that could have strong effects against SARS-CoV-2 infection.

2 Dec 2021

Natural triterpenoids in licorice found to inhibit SARS-CoV-2

In new studies, researchers concluded that licorice triterpenoids could be candidates for anti-SARS-CoV-2 drug developments.

2 Dec 2021

SARS-CoV-2 Delta spike increases viral virulence and inflammatory cytokine production

In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.

29 Nov 2021

Extended host range for SARS-CoV-2 variants of concern

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

29 Nov 2021

Study suggests making COVID vaccines based on Mu variant

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Mu variant (B.1.621, B.1.621.1) has been tagged as a Variant Being Monitored (VBM), and as of August 30, 2021, it had been detected in 39 countries.

28 Nov 2021

SARS-CoV-2 reinfection and the natural immune response

Researchers review available literature on immunity and SARS-CoV-2 infection to elucidate mechanisms behind SARS-CoV-2 immunity and reinfections.

24 Nov 2021

Tobacco mosaic virus nanoparticle-based novel COVID-19 vaccine candidate

Scientists generate a VLP type NP platform made of recombinant viral antigens conjugated with TMV virions.

23 Nov 2021

SARS-CoV-2 reinfection associated with housing instability

Researchers examine the impact of demographic factors and antibody responses following SARS-CoV-2 reinfection.

17 Nov 2021

Elderly residents of long-term care facilities benefit from booster vaccines against SARS-CoV-2

A recent study investigates whether markers of cellular and humoral immunity differ between adults over 75 and a control group six months after vaccination.

16 Nov 2021